Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial | MicrobiomeTrials← Back to trialsNCT06184750
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-09-27Est. Completion: 2028-03-31
Enrollment target: 200 participants Locations- University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona, United States
- Northwestern University, Chicago, Illinois, United States
- University of Illinois College of Medicine - Chicago, Chicago, Illinois, United States
- University of Kansas Cancer Center, Kansas City, Kansas, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Case Western Reserve University, Cleveland, Ohio, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- UT MD Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Breast Cancer
This study will explore new screening methods for early detection of breast and ovarian cancer in women at high risk for…
Bethesda, United States
Breast Atypical HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In SituBreast Lobular Carcinoma In Situ
This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenop…
Duarte, United StatesEst. completion Aug 23, 2027